Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 13, 2025

PE anti-mouse CD366 (Tim-3)

RRID:AB_1626177
Type: Antibody

Proper Citation

(BioLegend Cat# 134004, RRID:AB_1626177)

Antibody Information

URL: http://antibodyregistry.org/AB_1626177

Proper Citation: (BioLegend Cat# 134004, RRID:AB_1626177)

Target Antigen: CD366

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD366 (Tim-3)

Description: This monoclonal targets CD366

Target Organism: mouse

Clone ID: Clone B8.2C12

Antibody ID: AB_1626177

Vendor: BioLegend

Catalog Number: 134004

Alternative Catalog Numbers: 134003

Record Creation Time: 20231110T052356+0000

Record Last Update: 20241115T003758+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD366 (Tim-3).

No alerts have been found for PE anti-mouse CD366 (Tim-3).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. Cell reports, 43(9), 114690.

Tichet M, et al. (2023) Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. Immunity, 56(1), 162.

Mohammadpour H, et al. (2023) Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation. Cell reports, 42(3), 112250.

Peuker K, et al. (2022) Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity, 55(4), 701.

Edmunds GL, et al. (2022) Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization. Communications biology, 5(1), 9.

Li H, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer cell, 40(1), 36.

Xie A, et al. (2017) Anti-TCR? mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice. Endocrinology, 158(10), 3140.